Biden Era Ushers In New Breed of Clean-Energy Profit-Stocks
With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Here’s a brand new clean energy innovator, currently undiscovered at $2 per share, that’s deploying a world’s-first business model with 10X to 20X upside.
Get the details here...
pixel

HRTX Insider Trading (Heron Therapeutics)

Insider Ownership Percentage: 12.85%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $105,648.55

Heron Therapeutics Insider Trading History Chart

Heron Therapeutics Share Price & Price History

$16.60
▼ -0.67 (-3.88%)
As of 04/9/2021 01:00 AM ET
Days: 30 | 90 | 365
Breaking Now: Biden's Disturbing Plan to "Reset" America
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.
Go here before this message is removed.

Heron Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/6/2021Craig A JohnsonDirectorSell250$17.22$4,305.003,590  
1/14/2021David Leslie SzekeresCOOSell827$18.09$14,960.431,250  
1/8/2021David Leslie SzekeresCOOSell3,571$19.66$70,205.86  
5/1/2020Kimberly ManhardVPSell1,158$13.97$16,177.261,158  
11/29/2019Kimberly ManhardVPSell24,000$26.00$624,000.0024,000  
10/4/2019Kevin C TangDirectorBuy285,714$17.50$4,999,995.00  
10/3/2019Barry D QuartCEOBuy4,571$17.50$79,992.5090,081  
10/3/2019John PoyhonenEVPBuy5,143$17.50$90,002.5018,143  
9/30/2019John PoyhonenInsiderBuy11,105$22.62$251,195.10
5/22/2019John PoyhonenDirectorBuy3,000$17.55$52,650.0013,000  
5/15/2019Waage ChristianDirectorBuy1,400$18.04$25,256.001,400  
5/1/2019Kimberly ManhardVPSell1,109$18.86$20,915.741,109  
11/2/2018Kimberly ManhardVPSell494$30.62$15,126.28494  
10/1/2018Kimberly ManhardVPSell6,000$32.07$192,420.006,000  
9/12/2018Kevin C TangDirectorSell2,695,000$35.75$96,346,250.00  
7/2/2018Kimberly ManhardVPSell6,000$37.53$225,180.006,000  
7/2/2018Robert HoffmanCFOSell30,000$38.17$1,145,100.001,280  
7/2/2018Robert RosenPresidentSell225,000$38.98$8,770,500.00132,109  
6/29/2018Robert RosenPresidentSell129,469$39.59$5,125,677.71132,109  
6/21/2018Barry D QuartCEOSell50,000$39.05$1,952,500.0069,600  
See Full Table

SEC Filings (Institutional Ownership Changes) for Heron Therapeutics (NASDAQ:HRTX)

99.01% of Heron Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Heron Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
4/2/2021Private Asset Management Inc.192,853$3.13M0.4%+13.1%0.211%
3/26/2021Susquehanna International Group LLP119,777$2.54M0.0%+56.8%0.131%
3/19/2021Valley Brook Capital Group1,300$27K0.0%N/A0.001%
3/8/2021Dimensional Fund Advisors LP525,892$11.13M0.0%-2.2%0.575%
3/2/2021Norges Bank1,166,605$24.69M0.0%N/A1.276%
2/25/2021Dimensional Fund Advisors LP525,892$11.13M0.0%-2.2%0.579%
2/25/2021Hsbc Holdings PLC11,730$0.25M0.0%N/A0.013%
2/24/2021Virtu Financial LLC20,667$0.44M0.0%N/A0.023%
2/23/2021Pier 88 Investment Partners LLC48,410$1.03M0.2%+28.5%0.053%
2/23/2021Principal Financial Group Inc.40,953$0.87M0.0%+26.0%0.045%
2/19/2021PFM Health Sciences LP2,011,477$42.57M1.5%+7.5%2.214%
2/19/2021UBS Oconnor LLC600,000$12.70M0.2%-7.7%0.660%
2/19/2021JPMorgan Chase & Co.3,100,782$65.63M0.0%+4.1%3.413%
2/18/2021Truist Financial Corp22,801$0.48M0.0%+51.5%0.025%
2/17/2021IHT Wealth Management LLC21,061$0.45M0.0%+77.1%0.023%
2/17/2021UBS Oconnor LLC600,000$12.70M0.4%-7.7%0.660%
2/16/2021Morgan Stanley459,763$9.73M0.0%+144.7%0.506%
2/16/2021Nuveen Asset Management LLC444,535$9.41M0.0%-41.7%0.489%
2/16/2021Guggenheim Capital LLC33,738$0.71M0.0%+56.5%0.037%
2/16/2021Price T Rowe Associates Inc. MD70,498$1.49M0.0%-1.9%0.078%
2/16/2021Virginia Retirement Systems ET AL27,800$0.59M0.0%-21.9%0.031%
2/16/2021Charles Schwab Investment Management Inc.553,741$11.72M0.0%+2.0%0.609%
2/13/2021American International Group Inc.50,938$1.08M0.0%-2.8%0.056%
2/12/2021Stifel Financial Corp73,959$1.57M0.0%-7.4%0.081%
2/12/2021LPL Financial LLC12,210$0.26M0.0%-43.9%0.013%
2/12/2021Raymond James Financial Services Advisors Inc.17,195$0.36M0.0%+4.7%0.019%
2/12/2021The Manufacturers Life Insurance Company51,408$1.09M0.0%+3.8%0.057%
2/12/2021Credit Suisse AG144,369$3.06M0.0%-10.1%0.159%
2/12/2021Alpha Paradigm Partners LLC18,645$0.40M0.1%N/A0.021%
2/11/2021Northern Trust Corp999,360$21.15M0.0%-2.2%1.100%
2/11/2021Barclays PLC67,851$1.44M0.0%-4.9%0.075%
2/11/2021Citigroup Inc.21,124$0.45M0.0%+251.5%0.023%
2/11/2021Heartland Advisors Inc.200,000$4.23M0.3%-46.7%0.220%
2/11/2021Oppenheimer & Co. Inc.10,900$0.23M0.0%-14.8%0.012%
2/11/2021Palisade Capital Management LLC NJ890,618$18.85M0.5%+8.5%0.980%
2/11/2021Pekin Hardy Strauss Inc.466,437$9.87M1.8%-21.6%0.513%
2/11/2021Redmond Asset Management LLC51,115$1.08M0.4%+9.9%0.056%
2/11/2021Signaturefd LLC3,250$69K0.0%+160.0%0.004%
2/10/2021Mackenzie Financial Corp25,510$0.54M0.0%N/A0.028%
2/10/2021D.A. Davidson & CO.88,461$1.87M0.0%+10.0%0.097%
2/10/2021Clearbridge Investments LLC3,454,206$73.11M0.1%+0.5%3.802%
2/10/2021Panagora Asset Management Inc.516,852$10.94M0.1%-2.0%0.569%
2/10/2021Artisan Partners Limited Partnership1,343,212$28.43M0.0%+21.6%1.478%
2/9/2021Wells Fargo & Company MN209,801$4.44M0.0%-5.2%0.231%
2/9/2021ClariVest Asset Management LLC128,950$2.73M0.1%-25.1%0.142%
2/9/2021Bank of New York Mellon Corp355,365$7.52M0.0%-0.8%0.391%
2/9/2021Quantitative Systematic Strategies LLC32,137$0.68M0.1%N/A0.035%
2/9/2021ProShare Advisors LLC19,415$0.41M0.0%+80.7%0.021%
2/8/2021Rothschild & Co. Asset Management US Inc.1,352,754$28.63M0.4%-16.0%1.489%
2/8/2021New York State Common Retirement Fund229,351$4.85M0.0%+9.8%0.252%
2/8/2021Sei Investments Co.415,216$8.79M0.0%-10.6%0.457%
2/8/2021Russell Investments Group Ltd.178,476$3.78M0.0%+56.3%0.196%
2/5/2021Banque Cantonale Vaudoise2,000$42K0.0%+233.3%0.002%
2/5/2021BlackRock Inc.6,886,932$145.76M0.0%+18.2%7.580%
2/5/2021Aperio Group LLC12,801$0.27M0.0%+10.8%0.014%
2/5/2021Y Intercept Hong Kong Ltd19,351$0.41M0.2%N/A0.021%
2/5/2021C WorldWide Group Holding A S1,202,069$25.44M0.3%+33.3%1.323%
2/5/2021CM Management LLC15,000$0.32M0.3%N/A0.017%
2/5/2021SG Americas Securities LLC59,898$1.27M0.0%+11.5%0.066%
2/4/2021Searle & CO.37,750$0.80M0.4%-1.9%0.042%
2/4/2021Cutter & CO Brokerage Inc.33,340$0.71M0.2%+9.4%0.037%
2/4/2021State of Wisconsin Investment Board124,600$2.64M0.0%-11.1%0.137%
2/3/2021Oak Ridge Investments LLC266,415$5.64M0.5%-20.1%0.293%
2/3/2021State of New Jersey Common Pension Fund D141,265$2.99M0.0%-11.5%0.155%
2/2/2021Peak Financial Advisors LLC179,815$3.81M3.3%N/A0.198%
2/2/2021California Public Employees Retirement System189,383$4.01M0.0%-4.6%0.208%
2/2/2021First Trust Advisors LP17,953$0.38M0.0%-61.3%0.020%
2/1/2021Victory Capital Management Inc.14,307$0.30M0.0%+5.4%0.016%
1/29/2021Fisher Asset Management LLC33,078$0.70M0.0%-16.5%0.036%
1/28/2021Arizona State Retirement System25,031$0.53M0.0%-3.7%0.028%
1/28/2021Dupont Capital Management Corp29,095$0.62M0.0%-6.9%0.032%
1/26/2021Harel Insurance Investments & Financial Services Ltd.10,000$0.68M0.0%N/A0.011%
1/25/2021Nisa Investment Advisors LLC5,185$0.11M0.0%+22.4%0.006%
1/22/2021Candriam Luxembourg S.C.A.1,289,773$27.30M0.2%-2.2%1.420%
1/20/2021Pacer Advisors Inc.4,800$0.10M0.0%+19.8%0.005%
1/5/2021Private Asset Management Inc.170,514$3.61M0.5%-0.3%0.188%
12/4/2020Sei Investments Co.464,238$6.88M0.0%+266.9%0.511%
11/18/2020DSAM Partners London Ltd261,306$3.87M0.7%N/A0.288%
11/17/2020PFM Health Sciences LP1,872,012$27.74M1.3%-16.1%2.060%
11/17/2020Voloridge Investment Management LLC48,814$0.72M0.0%N/A0.054%
11/16/2020Cubist Systematic Strategies LLC12,609$0.19M0.0%-20.2%0.014%
11/16/2020Point72 Asset Management L.P.261,341$3.87M0.0%N/A0.288%
11/16/2020Squarepoint Ops LLC21,846$0.32M0.0%N/A0.024%
11/16/2020ExodusPoint Capital Management LP62,210$0.92M0.0%-11.0%0.068%
11/16/2020ArrowMark Colorado Holdings LLC5,059,526$74.98M0.7%-2.2%5.569%
11/16/2020Consonance Capital Management LP2,005,218$29.72M3.6%N/A2.207%
11/13/2020Morgan Stanley187,884$2.78M0.0%+104.7%0.207%
11/13/2020Truist Financial Corp15,051$0.22M0.0%-30.2%0.017%
11/13/2020ProShare Advisors LLC10,742$0.16M0.0%-9.8%0.012%
11/13/2020Charles Schwab Investment Management Inc.543,084$8.05M0.0%+0.6%0.598%
11/13/2020UBS Asset Management Americas Inc.94,398$1.40M0.0%+4.7%0.104%
11/13/2020Guggenheim Capital LLC21,564$0.32M0.0%N/A0.024%
11/12/2020UBS Oconnor LLC650,000$9.63M0.3%-3.7%0.715%
11/12/2020JPMorgan Chase & Co.2,978,595$44.20M0.0%+3.3%3.278%
11/12/2020Palisade Capital Management LLC NJ820,539$12.16M0.4%+21.5%0.903%
11/12/2020Oak Ridge Investments LLC333,501$4.94M0.4%-7.7%0.367%
11/12/2020Cerity Partners LLC35,600$0.53M0.0%-6.4%0.039%
11/12/2020Virginia Retirement Systems ET AL35,600$0.53M0.0%+75.4%0.039%
11/10/2020Fisher Asset Management LLC39,613$0.59M0.0%-31.1%0.044%
11/10/2020State Street Corp4,410,234$65.36M0.0%+14.8%4.854%
Data available starting January 2016

See Full Table
Heron Therapeutics logo
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $16.60
$16.52
$17.32

50 Day Range

MA: $16.90
$14.49
$19.31

52 Week Range

Now: $16.60
$12.52
$22.40

Volume

931,432 shs

Average Volume

1,020,290 shs

Market Capitalization

$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Who are the company insiders with the largest holdings of Heron Therapeutics?

Heron Therapeutics' top insider shareholders include:
  1. Barry D Quart (CEO)
  2. Kimberly Manhard (VP)
  3. John Poyhonen (EVP)
  4. John Poyhonen (Director)
  5. Craig A Johnson (Director)
  6. Waage Christian (Director)
  7. David Leslie Szekeres (COO)
  8. John Poyhonen (Insider)
  9. Kevin C Tang (Director)

Who are the major institutional investors of Heron Therapeutics?

Heron Therapeutics' top institutional shareholders include:
  1. Private Asset Management Inc. — 0.21%

Which institutional investors are buying Heron Therapeutics stock?

Within the last quarter, HRTX stock was purchased by institutional investors including:
  1. Private Asset Management Inc.
During the previous year, these company insiders have bought Heron Therapeutics stock:
  1. Barry D Quart (CEO)
  2. Kimberly Manhard (VP)
  3. John Poyhonen (EVP)
  4. John Poyhonen (Director)
  5. Craig A Johnson (Director)
  6. Waage Christian (Director)
Finance PhD: Move Your Money Before April 30th
The clock just starting ticking on the biggest financial event in 20 years. The next few weeks could decide your wealth in 2021.
See what you should do now